Insider Trading & Ownership of ORBIMED ADVISORS LLC
-
Location
-
New York, NY
-
Summary
-
The estimated value of insider holdings of ORBIMED ADVISORS LLC is at least $923,089,422 dollars as of 04 Feb 2026. ORBIMED ADVISORS LLC is the 10%+ Owner of SpringWorks Therapeutics, Inc. and owns shares of SpringWorks Therapeutics, Inc. stock worth about $232.56M. ORBIMED ADVISORS LLC is the Director, 10%+ Owner of Enliven Therapeutics, Inc. and owns shares of Enliven Therapeutics, Inc. (ELVN) stock worth about $169.67M. ORBIMED ADVISORS LLC is the Director of Sionna Therapeutics, Inc. and owns shares of Sionna Therapeutics, Inc. (SION) stock worth about $157.4M. ORBIMED ADVISORS LLC is the Director of Verona Pharma plc and owns shares of Verona Pharma plc (VRNA) stock worth about $75.56M. ORBIMED ADVISORS LLC is the Director, 10%+ Owner of Third Harmonic Bio, Inc. and owns shares of Third Harmonic Bio, Inc. stock worth about $59.52M. ORBIMED ADVISORS LLC is the 10%+ Owner of NeuroPace Inc and owns shares of NeuroPace Inc (NPCE) stock worth about $51.62M. ORBIMED ADVISORS LLC is the Director, 10%+ Owner of Prelude Therapeutics Inc and owns shares of Prelude Therapeutics Inc (PRLD) stock worth about $38.15M. ORBIMED ADVISORS LLC is the Director, 10%+ Owner of Corvus Pharmaceuticals, Inc. and owns shares of Corvus Pharmaceuticals, Inc. (CRVS) stock worth about $29.8M. ORBIMED ADVISORS LLC is the 10%+ Owner of 89bio, Inc. and owns shares of 89bio, Inc. stock worth about $21.09M. ORBIMED ADVISORS LLC is the 10%+ Owner of TELA Bio, Inc. and owns shares of TELA Bio, Inc. (TELA) stock worth about $10.93M. ORBIMED ADVISORS LLC is the Director of Venetian-1 Acquisition Corp. and owns shares of Lomond Therapeutics Holdings, Inc. stock worth about $10.71M. ORBIMED ADVISORS LLC is the Director of Disc Medicine, Inc. and owns shares of Disc Medicine, Inc. (IRON) stock worth about $10.09M. ORBIMED ADVISORS LLC is the Director, 10%+ Owner of Edgewise Therapeutics, Inc. and owns shares of Edgewise Therapeutics, Inc. (EWTX) stock worth about $8.93M. ORBIMED ADVISORS LLC is the Director, 10%+ Owner of MBX Biosciences, Inc. and owns shares of MBX Biosciences, Inc. (MBX) stock worth about $8.11M. ORBIMED ADVISORS LLC is the 10%+ Owner of PMV Pharmaceuticals, Inc. and owns shares of PMV Pharmaceuticals, Inc. (PMVP) stock worth about $7.56M. ORBIMED ADVISORS LLC is the Director, 10%+ Owner of Terns Pharmaceuticals, Inc. and owns shares of Terns Pharmaceuticals, Inc. (TERN) stock worth about $7.56M. ORBIMED ADVISORS LLC is the Director, 10%+ Owner of ArriVent Biopharma, Inc. and owns shares of ArriVent BioPharma, Inc. (AVBP) stock worth about $5.52M. ORBIMED ADVISORS LLC is the 10%+ Owner of Adicet Bio, Inc. and owns shares of Adicet Bio, Inc. (ACET) stock worth about $4.49M. ORBIMED ADVISORS LLC is the Director, 10%+ Owner of Acutus Medical, Inc. and owns shares of Acutus Medical, Inc. stock worth about $2.62M. ORBIMED ADVISORS LLC is the 10%+ Owner of Passage BIO, Inc. and owns shares of Passage BIO, Inc. (PASG) stock worth about $2M. ORBIMED ADVISORS LLC is the 10%+ Owner of Arcutis Biotherapeutics, Inc. and owns shares of Arcutis Biotherapeutics, Inc. (ARQT) stock worth about $1.47M. ORBIMED ADVISORS LLC is the Director of Janux Therapeutics, Inc. and owns shares of Janux Therapeutics, Inc. (JANX) stock worth about $1.36M. ORBIMED ADVISORS LLC is the Director, 10%+ Owner of Homology Medicines, Inc. and owns shares of Q32 Bio Inc. (QTTB) stock worth about $1.29M. ORBIMED ADVISORS LLC is the 10%+ Owner of Galecto, Inc. and owns shares of Galecto, Inc. (GLTO) stock worth about $1.13M. ORBIMED ADVISORS LLC is the 10%+ Owner of scPharmaceuticals Inc. and owns shares of scPharmaceuticals Inc. stock worth about $1.01M. ORBIMED ADVISORS LLC is the Director of Shattuck Labs, Inc. and owns shares of Shattuck Labs, Inc. (STTK) stock worth about $912K. ORBIMED ADVISORS LLC is the Director of Keros Therapeutics, Inc. and owns shares of Keros Therapeutics, Inc. (KROS) stock worth about $799.8K. ORBIMED ADVISORS LLC is the Director of ImageneBio, Inc. and owns shares of ImageneBio, Inc. (IMA) stock worth about $716.8K. ORBIMED ADVISORS LLC is the 10%+ Owner of Traws Pharma, Inc. and owns shares of Traws Pharma, Inc. (TRAW) stock worth about $282.9K. ORBIMED ADVISORS LLC is the Director of Repare Therapeutics Inc. and owns shares of Repare Therapeutics Inc. stock worth about $233.3K.
-
Signature
-
/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Follow Filing Activity
Follow ORBIMED ADVISORS LLC and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
Quick Takeaways
- ORBIMED ADVISORS LLC has 40 issuer positions tracked on this page.
- Estimated disclosed ownership value: $923,089,422.
- Recent insider filing activity is available below.
What Changed
- Largest disclosed position: SpringWorks Therapeutics, Inc. ($232,561,438).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original Filing
Continue ownership research
Ownership of ORBIMED ADVISORS LLC
| Symbol |
Company |
Relationship |
Holdings Value |
Past Year Net Change |
Change % |
Report Period |
| SWTX |
SpringWorks Therapeutics, Inc. |
10%+ Owner |
$232,561,438 |
|
|
12 Sep 2022 |
| ELVN |
Enliven Therapeutics, Inc. |
Director, 10%+ Owner |
$169,666,547 |
|
|
16 May 2024 |
| SION |
Sionna Therapeutics, Inc. |
Director |
$157,398,695 |
-$7,763,508 |
-4.7% |
02 Feb 2026 |
| VRNA |
Verona Pharma plc |
Director |
$75,555,560 |
|
|
11 May 2023 |
| THRD |
Third Harmonic Bio, Inc. |
Director, 10%+ Owner |
$59,522,120 |
|
|
19 Sep 2022 |
| NPCE |
NeuroPace Inc |
10%+ Owner |
$51,616,892 |
-$2,665,333 |
-4.9% |
14 May 2025 |
| PRLD |
Prelude Therapeutics Inc |
Director, 10%+ Owner |
$38,151,480 |
|
|
22 May 2023 |
| CRVS |
Corvus Pharmaceuticals, Inc. |
Director, 10%+ Owner |
$29,796,393 |
-$4,891,894 |
-14% |
27 Jun 2025 |
| ETNB |
89bio, Inc. |
10%+ Owner |
$21,093,397 |
|
|
25 Jan 2022 |
| TELA |
TELA Bio, Inc. |
10%+ Owner |
$10,928,879 |
|
|
28 Jun 2024 |
|
Venetian-1 Acquisition Corp. |
Director |
$10,709,024 |
|
|
01 Nov 2024 |
| IRON |
Disc Medicine, Inc. |
Director |
$10,093,734 |
|
|
24 Mar 2025 |
| EWTX |
Edgewise Therapeutics, Inc. |
Director, 10%+ Owner |
$8,933,533 |
|
|
03 Apr 2025 |
| MBX |
MBX Biosciences, Inc. |
Director, 10%+ Owner |
$8,107,095 |
|
|
14 Feb 2025 |
| PMVP |
PMV Pharmaceuticals, Inc. |
10%+ Owner |
$7,562,442 |
-$2,420,000 |
-24% |
23 Oct 2025 |
| TERN |
Terns Pharmaceuticals, Inc. |
Director, 10%+ Owner |
$7,556,350 |
|
|
15 Jul 2024 |
| AVBP |
ArriVent Biopharma, Inc. |
Director, 10%+ Owner |
$5,524,874 |
|
|
30 Jan 2024 |
| ACET |
Adicet Bio, Inc. |
10%+ Owner |
$4,490,254 |
+$5,000,000 |
+111% |
08 Oct 2025 |
| AFIB |
Acutus Medical, Inc. |
Director, 10%+ Owner |
$2,616,683 |
|
|
19 Jul 2021 |
| PASG |
Passage BIO, Inc. |
10%+ Owner |
$2,001,893 |
-$325,674 |
-14% |
24 Jun 2025 |
| ARQT |
Arcutis Biotherapeutics, Inc. |
10%+ Owner |
$1,469,935 |
|
|
24 Jun 2022 |
| JANX |
Janux Therapeutics, Inc. |
Director |
$1,356,545 |
|
|
29 Dec 2021 |
| QTTB |
Homology Medicines, Inc. |
Director, 10%+ Owner |
$1,286,681 |
|
|
25 Mar 2024 |
| GLTO |
Galecto, Inc. |
10%+ Owner |
$1,132,781 |
|
|
15 Aug 2023 |
| SCPH |
scPharmaceuticals Inc. |
10%+ Owner |
$1,011,432 |
|
|
13 Aug 2024 |
| STTK |
Shattuck Labs, Inc. |
Director |
$911,970 |
+$5,471,826 |
+600% |
25 Aug 2025 |
| KROS |
Keros Therapeutics, Inc. |
Director |
$799,761 |
|
|
21 Nov 2025 |
| IMA |
ImageneBio, Inc. |
Director |
$716,833 |
|
|
25 Jul 2025 |
| TRAW |
Traws Pharma, Inc. |
10%+ Owner |
$282,940 |
|
|
29 Dec 2024 |
| RPTX |
Repare Therapeutics Inc. |
Director |
$233,261 |
|
|
03 Sep 2021 |
| ALPN |
ALPINE IMMUNE SCIENCES, INC. |
Director |
$0 |
|
|
18 May 2024 |
| SPRY |
ARS Pharmaceuticals, Inc. |
Director |
$0 |
|
|
26 Aug 2024 |
| CMPX |
Compass Therapeutics, Inc. |
Director, 10%+ Owner |
$0 |
-$5,678,571 |
-100% |
09 Apr 2025 |
| KNTE |
Kinnate Biopharma Inc. |
Director, 10%+ Owner |
$0 |
|
|
03 Apr 2024 |
| THRX |
Theseus Pharmaceuticals, Inc. |
Director, 10%+ Owner |
$0 |
|
|
14 Feb 2024 |
| TSBX |
Turnstone Biologics Corp. |
Director |
$0 |
|
|
08 Aug 2025 |
| XTNT |
Xtant Medical Holdings, Inc. |
10%+ Owner |
$0 |
-$30,708,129 |
-100% |
10 Apr 2025 |
| SRRA |
Sierra Oncology, Inc. |
Director, 10%+ Owner |
|
|
|
01 Jul 2022 |
| TCDA |
Tricida, Inc. |
Director, 10%+ Owner |
|
|
|
22 Nov 2022 |
| UPB |
Upstream Bio, Inc. |
Director, 10%+ Owner |
|
|
|
15 Oct 2024 |
Insider Transactions Reported by ORBIMED ADVISORS LLC:
| Sym |
Company |
Class |
Transaction |
% |
Value $ |
* Price $ |
Shares |
Shares After |
Date |
Ownership |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.